Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25312196 | 0.90 | KDM1A (0.42) | OPRD1OPRK1CCR5CCNCCDK8 | |
| SCHEMBL24338260 | 0.87 | MEN1 (0.47) | OPRD1OPRK1CCR5ACHEMAPK1 | |
| SCHEMBL23041367 | 0.85 | OPRK1 (0.52) | OPRD1OPRK1CCR5ACHEMAPK1 | |
| SCHEMBL25875252 | 0.85 | CYP2D6 (0.46) | OPRD1OPRK1MAPK1KMT2A | |
| SCHEMBL21104902 | 0.85 | CYP2D6 (0.46) | OPRD1OPRK1MAPK1KMT2A | |
| SCHEMBL25875253 | 0.85 | CYP2D6 (0.46) | OPRD1OPRK1MAPK1KMT2A | |
| SCHEMBL25311909 | 0.85 | OPRL1 (0.42) | OPRD1OPRK1CRBNKMT2A | |
| SCHEMBL23540149 | 0.83 | MEN1 (0.45) | OPRD1OPRK1CCR5ACHEMAPK1 | |
| SCHEMBL25874982 | 0.83 | OPRM1 (0.45) | OPRD1OPRK1CRBNKMT2A | |
| SCHEMBL26426366 | 0.82 | OPRD1 (0.44) | OPRD1OPRK1ACHEUSP30HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490993-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2023-12-06 | — | — | EP | disclosed |
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4161517-A2 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS | Aptinyx Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| US-11376250-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-109890825-B | Spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20210322406-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-10-21 | — | — | US | disclosed |
| US-20210322406-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-10-21 | — | — | US | disclosed |
| US-10918637-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10918637-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2021021996-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | APTINYX INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20190175588-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-06-13 | — | — | US | disclosed |
| US-20190175588-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-06-13 | — | — | US | disclosed |
| EP-3490993-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018026782-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376250-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OPRD1 38/4885OPRK1 30/4885CCR5 1027/4885 |
| US-20190175588-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRD1 38/4885OPRK1 30/4885CCR5 1027/4885 |
| US-20210322406-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRD1 38/4885OPRK1 30/4885CCR5 1027/4885 |
| US-10918637-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OPRD1 38/4885OPRK1 30/4885CCR5 1027/4885 |
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | ACE, ACE2, PREP | OPRD1 2074/4885OPRK1 1849/4885CCR5 478/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | OPRD1 150/4885OPRK1 147/4885CCR5 3455/4885 |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRD1 38/4885OPRK1 30/4885CCR5 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.